Related Experiment Video
Updated: Jul 4, 2026
Three-Dimensional Cell Culture Models to Investigate the Epithelial Barrier in Eosinophilic Esophagitis
Published on: May 10, 2024
Therapeutic options for patients with clonal and idiopathic hypereosinophia
Alfonso Quintás-Cardama1, Jorge Cortes
1The University of Texas, MD Anderson Cancer Center, Department of Leukemia, Unit 428, 1515 Holcombe Blvd, Houston, TX 77030, USA. aquintas@mdanderson.org
Insights
New targeted therapies are revolutionizing hypereosinophilic syndrome (HES) treatment. Monoclonal antibodies and tyrosine kinase inhibitors offer new hope for patients with this complex blood disorder.
Area of Science:
- Hematology
- Oncology
- Immunology
Background:
- Hypereosinophilic syndrome (HES) is a group of disorders with chronic unexplained hypereosinophilia and organ damage.
- Novel molecular targets are transforming HES therapeutic strategies.
Purpose of the Study:
- To review current medical management for clonal and idiopathic hypereosinophilia.
- To highlight emerging targeted therapies for HES.
Main Methods:
- Literature review of public sources including journals and scientific meeting abstracts.
- Synthesis of information on current and novel HES treatments.
Main Results:
- Imatinib-resistant mutations drove the development of new tyrosine kinase inhibitors.
- Interleukin-5's role in lymphocytic HES and CD52 expression on eosinophils/T cells informed monoclonal antibody use.
Conclusions:
- Mepolizumab, reslizumab, and alemtuzumab are now used for various hypereosinophilia forms.
- Targeted therapies represent a significant advancement in HES management.
Background:
The hypereosinophilic syndrome (HES) comprises a heterogeneous group of disorders characterized by chronic, unexplained hypereosinophilia with organ involvement. The discovery of novel molecular targets has changed the therapeutic paradigm in HES.
Objective:
This article reviews the current medical management of patients with clonal and idiopathic hypereosinophilia with a particular emphasis on emerging new targeted therapies.
Methods:
The information contained in this review was obtained from public sources such as journals and scientific meeting abstracts. The opinions expressed in this review are solely those of the authors.
Results/Conclusion:
The development of imatinib-resistant mutations in the FIP1L1-PDGFR-alpha kinase domain has spurred the development of an array of new tyrosine kinase inhibitors. Moreover, the elucidation of the role of interleukin-5 in the pathogenesis of the lymphocytic variant of HES and the fact that CD52 is expressed on the surface of eosinophils and T cells have led to the clinical use of monoclonal antibodies such as mepolizumab, reslizumumab, and alemtuzumab for the treatment of different forms of hypereosinophilia.
Related Concept Videos
01:25Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
01:18Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
01:19Antiasthma Drugs: Leukotriene Modifiers
Leukotriene modifiers work through two distinct mechanisms:
01:27Tumor Immunotherapy
01:24Nephrotic Syndrome III : Nursing Management
01:20Asthma: Pathogenesis and Management
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.